Seagen to Host Conference Call and Webcast Discussion of First Quarter 2021 Financial Results on April 29, 2021Business Wire • 04/07/21
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab VedotinPRNewsWire • 03/26/21
Seattle Genetics (SGEN) Down 12.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/13/21
Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment CorporationBusiness Wire • 03/05/21
Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial CancerZacks Investment Research • 02/19/21
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial CancerBusiness Wire • 02/18/21
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial CancerPRNewsWire • 02/18/21
Seagen (SGEN) Gets European Commission Nod for Breast Cancer DrugZacks Investment Research • 02/15/21
Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin ChemotherapyBusiness Wire • 02/12/21
Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial CancerBusiness Wire • 02/12/21
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial CancerPRNewsWire • 02/12/21
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin ChemotherapyPRNewsWire • 02/12/21
European Commission Approves Seagen's TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast CancerBusiness Wire • 02/12/21
Seagen' (SGEN) CEO Clay Siegall on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/12/21
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 02/10/21